Because there is no Retatrutide-specific approved label, every safety statement on this page is class-level extrapolation from the established GLP-1 receptor-agonist labeling the boxed thyroid C-cell warning, the pancreatitis and gallbladder monitoring guidance, the hypoglycemia interaction with insulin and sulfonylureas
Horton, F., Wright, J., Smith, L., Hinton, P
But rare does not mean irrelevant, especially when you are making decisions about your own body
How DSIP might act in the body DSIP is discussed as a brain-active peptide, but its exact receptor picture is still unclear
They are not regulated in the same way as licensed weight loss treatments and do not come with medical assessment, dose control or ongoing supervision